(+)-4-[(ΑR)-Α-((2S,5R)-4-烯丙基-2,5-二甲基-1-哌嗪基)-3-甲氧基苄基]-N,N-二乙基苯酰胺
中文名称 | (+)-4-[(ΑR)-Α-((2S,5R)-4-烯丙基-2,5-二甲基-1-哌嗪基)-3-甲氧基苄基]-N,N-二乙基苯酰胺 |
---|---|
中文同义词 | (+)-4-[(ΑR)-Α-((2S,5R)-4-烯丙基-2,5-二甲基-1-哌嗪基)-3-甲氧基苄基]-N,N-二乙基苯酰胺;4-[(R)-[(2S,5R)-2,5-二甲基-4-(2-丙烯-1-基)-1-哌嗪基](3-甲氧基苯基)甲基]-N,N-二乙基苯甲酰胺;化合物SNC80;(+)-4-[(ΑR)-Α-((2S,5R)-4-烯丙基-2,5-二甲基-1-哌嗪基)-3-甲氧基苄基]-N,N-二乙基苯酰胺;SNC80,Δ阿片受体激动剂 |
英文名称 | SNC 80 |
英文同义词 | (+)-4-[(alphaR)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide;4-[(R)-[(2S,5R)-2,5-Dimethyl-4-(2-propen-1-yl)-1-piperazinyl](3-methoxyphenyl)methyl]-N,N-diethylbenzamide;(+)-4-[(Ar)-alpha-((2s,5r)-4-allyl-2,5-dimethyl-1-piperazinyl)-3;NIH 10815;(+)-4-[(AR)-A-((2S,5R)-4-ALLYL-2,5-DIMETHYL-1-PIPERAZINYL)-3-METHOXYBENZYL]-N,N-DIETHYLBENZAM;(+)-4-[(AR)-A-((2S,5R)-4-ALLYL-2,5-DIMETHYL-1-PIPERAZINYL)-3-METHOXYBENZYL]-N,N-DIETHYLBENZAMIDE;(+)-4-[(AR)-ALPHA-((2S,5R)-4-ALLYL-2,5-DIMETHYL-1-PIPERAZINYL)-3-METHOXYBENZYL]-N,N-DIETHYLBENZAMIDE;SNC 80 |
CAS号 | 156727-74-1 |
分子式 | C28H39N3O2 |
分子量 | 449.63 |
EINECS号 | |
相关类别 | Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Chiral Reagents;Opioid receptor and opioid-like receptor |
Mol文件 | 156727-74-1.mol |
结构式 |
(+)-4-[(ΑR)-Α-((2S,5R)-4-烯丙基-2,5-二甲基-1-哌嗪基)-3-甲氧基苄基]-N,N-二乙基苯酰胺 性质
熔点 | 122-123°C |
---|---|
沸点 | 564.8±50.0 °C(Predicted) |
密度 | 1.040 |
储存条件 | Store at RT |
溶解度 | 可溶于DMSO |
形态 | 固体 |
酸度系数(pKa) | 7.29±0.10(Predicted) |
颜色 | 米白色 |
稳定性 | 冷冻储存 |
InChIKey | KQWVAUSXZDRQPZ-UMTXDNHDSA-N |
SMILES | C(N(CC)CC)(=O)C1=CC=C([C@@H](N2C[C@@H](C)N(CC=C)C[C@@H]2C)C2=CC=CC(OC)=C2)C=C1 |
IC50: 2.73 nM (δ-opioid receptor), 5457 nM (μ-opioid receptor)
Ki: 1.78 nM (δ-opioid receptor), 881.5 nM (μ-opioid receptor) and 441.8 nM (κ-opioid receptor)
SNC80 selectively activates μ-δ heteromer in HEK293 cells with an EC 50 of 52.8 nM. SNC80 exhibits substantially greater activity in cells coexpressing μ- and δ-opioid receptors than in cells either singly expressing δ-opioid receptors or coexpressing δ- and κ-opioid receptors.
SNC80 (10 mg/kg; intraperitoneal injection; once; C57BL6/J mice) treatment significantly attenuated this allodynia caused by overuse of Sumatriptan.
Animal Model: | Male and female C57BL6/J mice (20-30g) injected with Sumatriptan |
Dosage: | 10 mg/kg |
Administration: | Intraperitoneal injection; once |
Result: | Significantly attenuated allodynia. |
A highly selective and potent non-peptide Δ9-agonist, 2000-fold selective over u-receptors.
安全信息
WGK Germany | 3 |
---|
提供商 | 语言 |
---|---|
英文
|